Introduction {#S1}
============

TAFRO syndrome is a clinical subtype of idiopathic multicentric Castleman disease (iMCD) characterized by [**t**]{.ul}hrombocytopenia, [**a**]{.ul}nasarca, [**f**]{.ul}ever, [**r**]{.ul}eticulin fibrosis/[**r**]{.ul}enal dysfunction, and [**o**]{.ul}rganomegaly \[[@R1], [@R2]\]. iMCD-TAFRO can occur in individuals of all ages, with a median age of 50 and a slight predilection for male gender \[[@R3]\]. Similar to other cases of iMCD, iMCD-TAFRO patients often present with elevated serum cytokines and chemokines including IL-6, IP-10, MDC, and CXCL13 \[[@R4], [@R5]\]. The etiology of iMCD-TAFRO and the basis for cytokine hypersecretion has not been elucidated, although germline and somatic genetic alterations have been proposed to underlie iMCD-TAFRO \[[@R6]\]. Here we report the identification and functional characterization of a somatic *MEK2* mutation and a germline *RUNX1* mutation in two iMCD-TAFRO patients, respectively.

Results and Discussion {#S2}
======================

Identification of somatic *MAP2K2* (*MEK2*) mutation and germline *RUNX1* mutation in patients with iMCD-TAFRO {#S3}
--------------------------------------------------------------------------------------------------------------

Clinical information was provided by treating physicians and extracted from electronic medical records. Studies were approved by the Institutional Review Boards of Memorial Sloan Kettering Cancer Center. Three patients (male, 32-year-old, 3-year-old and 20-year-old) presented with typical signs and symptoms of iMCD-TAFRO including fever, anasarca, leukocytosis, anemia, thrombocytopenia, renal insufficiency, hepatosplenomegaly, diffuse lymphadenopathy, and evidence of systemic inflammation with elevated ESR, CRP, and IL-6 levels ([Table 1](#T1){ref-type="table"}). Evaluation for autoantibodies and viruses (HHV-8, EBV) were negative. Lymph node excisional biopsies (neck and inguinal nodes, respectively) were compatible with iMCD-TAFRO ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}) \[[@R7]\]. Bone marrow biopsies revealed moderately increased megakaryocytes with occasional megakaryocytic emperipolesis and increased reticulin fibrosis. Flow cytometric analyses of nodal and marrow specimens were negative for lymphoma or leukemia. The overall findings were compatible with iMCD-TAFRO. All 3 patients were treated with high-dose steroids and anti-IL-6 antibodies (2 Tocilizumab and 1 Siltuximab) and obtained complete remission of symptoms including lymphadenopathy ([Fig. 1b](#F1){ref-type="fig"}, [1c](#F1){ref-type="fig"}).

In order to evaluate for potential genetic alterations underlying iMCD-TAFRO, the coding region of \~500 genes implicated in cancer was sequenced by a next generation sequencing platform (MSK-IMPACT) on the lymph node biopsy tissue from the three patients. Several germline variants of unclear significance were detected ([Table 2](#T2){ref-type="table"}). Among these variants, mutations in *MEK2* and *RUNX1* are commonly identified in a variety of cancers and were predicted to be damaging by both SIFT and Polyphen-2 programs. In addition, sequencing of the lymph node from Patient 1 identified a *MAP2K2* (*MEK2*) p.P128L mutation with a variant allele frequency (VAF) of 10%, which was absent from the patient's bone marrow, indicative of a somatic mutation. Although the function of this specific mutant has not been characterized previously, it is recurrent across several cancer types and predicted to activate MAPK signaling ([Fig. 1d](#F1){ref-type="fig"}). Sequencing of Patient 2 identified a RUNX1 p.G60C variant with similarly high VAF across nodal (48%), marrow (49%), and nail DNA (49%), indicative of a germline variant. RUNX1 p.G60C, located at the N-terminus of the RUNT DNA binding domain ([Fig. 1e](#F1){ref-type="fig"}), has not been previously reported but is structurally predicted to affect the heterodimerization of RUNX1 with CBFβ, which is essential for RUNX1 function ([Fig. 1f](#F1){ref-type="fig"}). We also examined for possible fusions by targeted next generation RNA sequencing (199-gene Archer panel) in all three patients but no in-frame fusions were detected. Based on these observations, we chose *MEK2* and *RUNX1* variants for further functional studies, although we cannot completely exclude the possibility that the other variants (such as *RARA* and *SETD2* variants in patient 3) could also be pathogenic.

Pathogenetic roles of mutant MEK2 and mutant RUNX1 {#S4}
--------------------------------------------------

To determine the functional impact of the somatic *MEK2* mutation, we expressed wild-type (WT) MEK2 and MEK2^P128L^ into 32D cells and examined the effects on IL-3 dependent growth and downstream signaling. Although MEK2^P128L^ did not confer cytokine independence, 32D cells expressing MEK2^P128L^ had robust growth at very low IL-3 concentrations in which control cells could not survive ([Fig. 2a](#F2){ref-type="fig"}, [2b](#F2){ref-type="fig"}), demonstrating cytokine hypersensitivity conferred by MEK2^P128L^. Accordingly, MEK2^P128L^ enhanced phosphorylation of MEK1/2 and downstream ERK1/2 constitutively and after IL-3 stimulation ([Fig. 2c](#F2){ref-type="fig"}). Although, BaseScope technology detected MEK2^P128L^ mRNA in a minor subset of cells in the nodal biopsy ([Supplementary Fig. S1b](#SD1){ref-type="supplementary-material"}), levels of phospho-ERK1/2 by immunohistochemistry were increased in the biopsy tissue and corresponded to histiocytes and/or follicular dendritic cells ([Fig. 2d](#F2){ref-type="fig"}) while lymphocytes had no detectable phospho-ERK. Consistent with these observations, 32D cells expressing MEK2^P128L^ were sensitive to various MEK inhibitors (Trametinib, Selumetinib, and U0126) ([Fig. 2e](#F2){ref-type="fig"}, [Supplementary Fig. S2a](#SD1){ref-type="supplementary-material"}, [2b](#F2){ref-type="fig"}), demonstrating suppressed cell growth and ERK activation in a dose-dependent manner ([Fig. 2f](#F2){ref-type="fig"}, [2g](#F2){ref-type="fig"}, [Supplementary Fig. S2c](#SD1){ref-type="supplementary-material"}-[e](#SD1){ref-type="supplementary-material"}), suggesting that inhibition of MAPK pathway could be a potential therapeutic strategy for iMCD-TAFRO. Interestingly, phospho-ERK expressing cells were also increased in patient 2 with the *RUNX1*^G60C^ mutation ([Fig. 2d](#F2){ref-type="fig"}). These results suggest that the MAP kinase pathway might be commonly activated in iMCD-TAFRO.

Unlike MEK2^P128L^, expression of RUNX1^G60C^ did not affect the growth of 32D cells (data not shown). However, given the location of this mutation within the RUNT DNA binding domain, we investigated the effect of mutant RUNX1^G60C^ on RUNX1 transcriptional activity. Using a luciferase reporter assay for a well-known RUNX1 target gene, M-CSFR, RUNX1^WT^ clearly induced RUNX1 transcriptional activity, an effect completely abolished in the presence of RUNX1^G60C^ ([Fig. 2h](#F2){ref-type="fig"}). Furthermore, RUNX1^G60C^ suppressed the activity of its WT counterpart, suggesting a dominant negative effect ([Fig. 2i](#F2){ref-type="fig"}, [Supplementary Fig. S2f](#SD1){ref-type="supplementary-material"}). As patients with germline *RUNX1* mutations are predisposed to myeloid neoplasms, we transduced RUNX1^G60C^ into mouse BM progenitor cells and performed colony-forming assay. MEK2^P128L^ had no effect on number or types of primary colonies and showed mildly increased colonies at second passage with no impact on serial replating capacity, suggesting that MEK2^P128L^ does not affect self-renewal capacity. In contrast, RUNX1^G60C^ significantly enhanced self-renewal capacity of BM progenitors to the same extent as the RUNX1/RUNX1T1 fusion ([Fig. 2j](#F2){ref-type="fig"}, [2k](#F2){ref-type="fig"}, [Supplementary Fig. S2g](#SD1){ref-type="supplementary-material"}). Somatic *MEK2* mutations occur in histiocytoses \[[@R8]\] while somatic *RUNX1* mutations occur in myeloid neoplasms and are associated with predisposition to myeloid neoplasms when present in the germline \[[@R9], [@R10]\]. These results suggest that iMCD-TAFRO might be related to a wider spectrum of diseases that converge on the same constellation associated with cytokine/chemokine hypersecretion. In fact, expression of both MEK2^P128L^ and RUNX1^G60C^ induced overproduction of some of the key cytokines/chemokines known to be elevated in iMCD-TAFRO including IL-6, IP-10, and MDC \[[@R4], [@R5]\] ([Supplementary Fig. S3a](#SD1){ref-type="supplementary-material"}-[c](#SD1){ref-type="supplementary-material"}).

The data above identify pathogenic genetic variants in two out of three subjects studied with iMCD-TAFRO. Although, a *DNMT3A* mutation was previously reported in an iMCD-TAFRO patient \[[@R11]\], the causative relationship of this mutation to iMCD-TAFRO is uncertain as *DNMT3A* is frequently mutated in clonal hematopoiesis \[[@R12], [@R13]\]. Another study reported a germline *FASL* mutation in a family with unicentric Castleman disease and iMCD \[[@R14]\]. However, germline *FASL* mutations are nearly pathognomonic for autoimmune lymphoproliferative syndrome, a condition that can resemble Castleman disease \[[@R15]\]. Instead, here we identified germline and somatic mutations in iMCD-TAFRO patients which have been implicated in clonal hematopoietic disorders and we demonstrate impact on gene function. These results suggest that iMCD-TAFRO might share pathogenetic features with these other clonal inflammatory disorders.

Materials and methods {#S5}
=====================

Patient Samples {#S6}
---------------

Tissues were obtained from three patients with iMCD-TAFRO. Clinical information was provided by treating physicians. Studies were approved by the Institutional Review Boards of Memorial Sloan Kettering Cancer Center (under MSK IRB protocol X17-025). Written informed consent was obtained from the three participants.

Mutational analysis of patient samples {#S7}
--------------------------------------

Targeted sequencing for recurrent mutations was done by MSK-IMPACT \[[@R16]\] targeting all coding regions of 585 genes known to be recurrently mutated in leukemias, lymphomas, and solid tumors. Targeted next generation RNA sequencing platform (199-gene Archer panel) was also performed.

Cell culture and cytokine measurement {#S8}
-------------------------------------

THP-1 (human acute monocytic leukemia cell line), HEK293T (cell line derived from human embryonic kidney 293 cells), and 32D (32Dcl3; murine myeloblast-like cell line) cells were cultured in IMDM/10% FCS (Fetal Calf Serum, heat inactivated), DMEM/10% FCS, and IMDM/10% FCS + mIL3 (R&D Systems; 1 ng/mL), respectively. None of the cell lines above were listed in the data base of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. For the cytokine/chemokine measurement, 1 × 10^6^ THP-1 cells were cultured in a 6-well plate and treated with phorbol 12-myristate 13-acetate (PMA; Millipore Sigma) at 10 ng/mL to induce differentiation into macrophage-like cells. The supernatant was collected at 72 hrs and the cytokine concentrations were measured using MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel (Millipore) by following instruction provided by the manufacturer. Standard curves were analyzed using Millipore Milliplex Analyst 5.1 Software.

Retroviral transduction and serial replating assays {#S9}
---------------------------------------------------

Bone marrow (BM) cells from 5-fluoruracil (150 mg/kg) treated C57BL/6 mice were extracted as previously described \[[@R17]\]. RBCs were removed by ACK lysis buffer, and nucleated BM cells were transduced with viral supernatants containing MSCV-RUNX1^WT/G60C^-IRES-GFP, MSCV-RUNX1/RUNX1T1-IRES-GFP, or MSCV-MEK2^WT/P128L^-IRES-GFP for 2 days in RPMI/20% FCS supplemented with mouse stem cell factor (mSCF; 25 ng/mL; R&D Systems), mouse IL-3 (mIL3; 10 ng/mL; R&D Systems), and mIL-6 (10 ng/mL; R&D Systems). GFP-sorted cells were used for the following serial replating assays as described \[[@R17]\]. Briefly, single-cell suspension was prepared and 15,000 cells/1.5 mL were plated in triplicate in cytokine supplemented methylcellulose medium (MethoCult™ GF M3434; StemCell Technologies), and colonies were enumerated weekly.

Reporter assay {#S10}
--------------

Analysis of luciferase activity was performed as described previously \[[@R18]\]. Cells were transfected with a M-CSF receptor (M-CSFR) \[[@R19]\] plasmid (and expression vectors for RUNX1^WT^ and RUNX1^G60C^) using Polyethylenimine (Polysciences, Inc.). Transfected cells were harvested 48 hours later and assayed for luciferase activity with a dual luciferase kit (Promega). Firefly luciferase activity was measured as relative light units. Relative light units from individual transfection were normalized by measurement of Renilla luciferase activity in the same samples. Relative M-CSFR promoter activity was presented as the ratio of normalized luciferase activity of empty vector-transduced cells.

Histological analyses {#S11}
---------------------

Bone marrow biopsies from the patients were decalcified and fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Paraffin blocks were sectioned at 4 μm and stained with hematoxylin and eosin (H&E). Immunohistochemical staining was performed using anti-phosphor-ERK antibody (clone D13.14.4E, Cell signaling Technology). Images were acquired using an Olympus microscope.

RNA in situ mutation detection (BaseScope) assay {#S12}
------------------------------------------------

RNA in situ hybridization experiments were performed using RNAscope®, an RNA in situ hybridization technique described previously \[[@R20], [@R21]\]. Paired double-Z oligonucleotide probes were designed against target RNA using custom software. The following probes were used: I-BA-Hs-MAP2K2-P128L-Cand1, cat no. 720821, NM_030662.3, 1zz pair, nt 610-643; I-BA-Hs-MAP2K2-P128WT-Cand1, cat no. 720841, NM_030662.3, 1zz pair, nt 611-642. The BaseScope™ Reagent Kit (Advanced Cell Diagnostics, Newark, CA) was used according to the manufacturer's instructions. FFPE cell and tissue sections were prepared according to manufacturer's recommendations. Each sample was quality controlled for RNA integrity with a 1zz probe specific to the housekeeping gene PPIB. Negative control background staining was evaluated using a 1zz probe specific to the bacterial dapB gene.

Cell culture {#S13}
------------

THP-1 (human acute monocytic leukemia cell line), HEK293T (cell line derived from human embryonic kidney 293 cells), and 32D (32Dcl3; murine myeloblast-like cell line) cells were cultured in IMDM/10% FCS (Fetal Calf Serum, heat inactivated), DMEM/10% FCS, and IMDM/10% FCS + mIL3 (R&D Systems; 1 ng/mL), respectively. None of the cell lines above were listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample.

Antibodies and reagents {#S14}
-----------------------

For western blotting, the following antibodies were used: Phospho-MEK1/2 (Ser217/221) (Cell Signaling Technologies; \#9154S), MEK1/2 (Cell Signaling Technologies; \#9126S), Phospho-p44/42 MAPK (Erk1/2) (thr202/Tyr204) (Cell Signaling Technologies; \#4370S), p44/42 MAPK (Erk1/2) (Cell Signaling Technologies; \#4695S), β-actin (Sigma-Aldrich; A-5441). Trametinib (GSK1120212) (S2673), Selumetinib (AZD6244) (S1008), and U0126-EtOH (S1102) were perchased from Selleckchem.

Statistics and reproducibility {#S15}
------------------------------

Statistical significance was determined by (1) unpaired two-sided Student's t-test after testing for normal distribution, (2) one-way or two-way ANOVA followed by Tukey's, Holm-Sidak's, or Dunnett's multiple comparison test, or (3) Kruskal-Wallis tests with Uncorrected Dunn's test where multiple comparisons should be adjusted. Representative WB results are shown from three or more than three biologically independent experiments.

Data availability {#S16}
-----------------

The data that support the findings of this study are available from the corresponding author upon reasonable request. Sequencing data have been deposited in NCBI ClinVar under accession number SCV000965590-SCV000965596. Other data that support this study's findings are available from the authors upon reasonable request.
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![Clinical presentation and genetic features of patients with iMCD-TAFRO.\
**a** Hematoxylin & eosin (H&E) and reticulin stain of a lymph node (LN) and bone marrow (BM) at diagnosis and after treatment (Patient 2; magnifications are indicated). **b, c** Representative plain CT (**b**) and PET scan (**c**) images of Patient 2 at diagnosis and after treatment. **d, e** Lollipop graphs showing frequencies of mutations in *MEK2* (**d**) and *RUNX1* (**e**) across cancers. Figures were made based on the cBioPortal data of 42,049 samples derived from TCGA PanCancer Atlas Studies and curated set of non-redundant studies (158 studies in total) and the location of mutations that were identified in Patient 1 and 2 are highlighted. Mutations affecting MEK2^P128^ were identified in 3 bladder carcinoma, 1 melanoma, and 1 pancreatic ductal adenocarcinoma. **f** Structure of WT Runt homology domain (white) and CBFβ (gray) with RUNX1^G60C^ position highlighted in red. Figure was made based on PDB ID: 1E50.](nihms-1554689-f0001){#F1}

![Pathogenic roles of mutant MEK2 and mutant RUNX1.\
**a, b** Cell growth of isogenic 32D cells cultured with various concentration of mouse IL-3 (**a**). Heatmaps were made based on relative cell growth of MEK2^WT^ and MEK2^P128L^ expressing cells compared to EV (empty vector)-transduced cells in **b** (*n* = 3 per genotype; the mean percentage ± standard deviation (SD); two-way ANOVA with Dunnett's multiple comparison test). **c** Representative western blot (WB) analysis of isogenic 32D cells from three biologically independent experiments with similar results. Experimental design is shown above. **d** Representative immunohistochemistry of phospho-ERK1/2 for the lymph nodes from both patient 1 and 2 as well as a normal tonsil as a control (original magnification x100). **e** Dose response curves of isogenic 32D cells to trametinib (*n* = 3; the mean value ± SD is shown). IC~50~ value for each genotype is indicated. **f** Cell growth of isogenic 32D cells cultured with various concentration of trametinib. Heatmaps were made based on relative cell growth of MEK2^WT^ and MEK2^P128L^ expressing cells compared to EV (empty vector)-transduced cells in [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}-[e](#SD1){ref-type="supplementary-material"}. **g** Representative WB analysis of isogenic 32D cells from three biologically independent experiments with similar results. **h** Luciferase activity of isogenic THP-1 cells retrovirally transduced with indicated constructs (top) and representative WB analysis of the same cells using an antibody against RUNX1 which recognizes N-terminus of RUNX1 protein (bottom). These cells were transfected with a M-CSF receptor reporter plasmid, and luciferase activities were measured as previously described \[[@R18]\] and presented as the fold change relative to EV-transduced cells (AE: RUNX1/RUNX1T1 (AML1/ETO); *n* = 3; the mean + SD; one-way ANOVA followed by Holm-Sidek's multiple comparison test). **i** Luciferase activity of HEK293T cells transfected with the reporter plasmid and mammalian expression vectors for RUNX1^WT^ and RUNX1^G60C^ at various doses as indicated (data are shown as in **h**). **j, k** Results of serial replating assays using primary mouse BM cells transduced with indicated constructs (*n* = 3 per genotype). Number of colonies (**j**) (the mean ± SD; two-way ANOVA with Tukey's multiple comparison test; *p*-values compared to EV-expressing cells are shown), and representative images of colonies (**k**) (original magnification x 20) are shown. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](nihms-1554689-f0002){#F2}

###### 

Clinicopathologic features of iMCD-TAFRO patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        Patient 1                            Patient 2                                         Patient 3
  ------------------------------------- ------------------------------------ ------------------------------------------------- -------------------------------------------------
  Age (years)                           32                                   3                                                 20

  Sex                                   M                                    M                                                 M

  Fever                                 Yes                                  Yes                                               Yes

  Anasarca                              Large pleural effusion and ascites   Pleural effusion, ascites, pericardial effusion   Pleural effusion, ascites, pericardial effusion

  Hb (g/dL)                             10.8                                 7.8                                               5.1

  PLT (x10^3^/dL)                       32                                   14                                                100

  ALP (U/L)                             Not available                        108                                               300

  LDH (U/L)                             Not available                        481                                               409

  Viral workup\                         Negative                             Negative                                          Negative
  (EBV/HHV-8/adenovirus/rhinovirus)                                                                                            

  Autoantibodies                        Negative                             Negative                                          Negative

  Renal insufficiency                   Yes                                  Yes                                               Yes (Hemodialysis)

  Organomegaly                          Yes                                  Yes                                               Yes

  Lymphadenopathy                       Diffuse                              Diffuse                                           Diffuse

  Castleman like changes in node        Yes                                  Yes                                               Yes

  Flow cytometry in node                Negative                             Negative                                          Negative

  Bone marrow atypical megakaryocytes   Yes                                  Yes                                               Yes

  Bone marrow fibrosis                  Yes (MF1-2/3)                        Yes (MF1/3)                                       Yes (MF1-2/3)

  Bone marrow flow cytometry            Negative                             Negative                                          Negative

  JAK2/MPL/CALR mutations               Negative                             Negative                                          Negative

  Serum IL-6 level                      43.6 pg/mL                           Significantly increased                           138.2 pg/mL

  Anti-IL-6 treatment                   Tocilizumab                          Tocilizumab                                       Siltuximab

  Steroids treatment                    Yes                                  Yes                                               Yes

  Follow-up                             Recovered, but relapsed              Recovered, no relapse for 3 years                 Recovered
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Variants detected in iMCD-TAFRO patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
              Gene              Protein change   Allele\   Chr.        Start Pos.   End pos.   Ref   Var            SIFT\               Polyphen-2\
                                                 Freq.                                                              prediction          prediction
  ----------- ----------------- ---------------- --------- ----------- ------------ ---------- ----- -------------- ------------------- -------------------
  Patient 1   *MAP2K2 (MEK2)*   P128L            0.10      19          4110574      4110574    G     A              Damaging            Probably damaging

  *AR*        A646D             0.99             X         66931295    66931295     C          A     Tolerated      Benign              

  *TCF3*      N347T             0.49             19        1621020     1621020      T          G     Tolerated      Probably damaging   

  *ARID2*     T1193A            0.46             12        46245483    46245483     A          G     Tolerated      Benign              

  Patient 2   *KMT2B (MLL4)*    E373del          0.40      19          36211355     36211357   AAG   A              \-                  \-

  *MPEG1*     L221I             0.50             11        58979678    58979678     G          T     Tolerated      Benign              

  *RUNX1*     G60C              0.48             21        36259232    36259232     C          A     Damaging       Probably damaging   

  Patient 3   *EGFR*            H145R            0.46      7           55214308     55214308   A     G              Tolerated           Benign

  *EPHA3*     S662T             0.52             3         89462392    89462392     T          G     Tolerated      Benign              

  *RARA*      G248D             0.53             17        38508695    38508695     G          A     Damaging       Probably damaging   

  *SOX9*      T316A             0.44             17        70119944    70119944     A          A     Tolerated      Benign              

  *SESN1*     H47R              0.48             6         109415137   109415137    T          C     Tolerated      Benign              

  *SETD2*     G1649E            0.46             3         47143017    47143017     C          T     Damaging       Probably damaging   

  *ANKRD11*   A2284V            0.47             16        89346099    89346099     G          A     (not scored)   Benign              

  *TET3*      V1137I            0.49             2         74327729    74327729     G          A     Tolerated      Benign              

  *ZFHX3*     Q3203_Q3204del    0.28             16        72822564    72822569     TGCTGC     \-    \-             \-                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------
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